A revolutionary cancer treatment protocol has been published, integrating Ivermectin, Mebendazole, and Fenbendazole, signaling a potential shift in oncology practices. The paper, titled “Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol,” appeared in the Journal of Orthomolecular Medicine on November 3, 2024.
William Makis MD announced the publication on social media, expressing gratitude to the lead authors Ilyes Baghli and Pierrick Martinez for their efforts. He emphasized the significance of this peer-reviewed paper in establishing a new direction for cancer treatment.
Makis has previously advocated for the use of high-dose Ivermectin and related medications, claiming success with thousands of cancer patients. He expressed hope that this new protocol would lead to further advancements in the fight against cancer.
The study proposes a novel theory known as the mitochondrial-stem cell connection (MSCC), suggesting that cancer may arise from a deficiency in oxidative phosphorylation (OxPhos) within stem cells. This deficiency can result in the formation of cancer stem cells (CSCs), ultimately leading to malignancy.
The manuscript outlines seven therapeutic recommendations aimed at enhancing OxPhos and targeting the primary fuels of cancer cells, such as glucose and glutamine. It aims to inhibit CSCs and metastasis, potentially offering a new therapeutic avenue for cancer treatment.
This protocol integrates established theories from cancer research, combining insights from molecular biology and clinical studies. The authors assert that targeting the MSCC could represent a significant advancement in cancer therapy.
The publication has garnered attention amid growing concerns over conventional oncology practices and their response to recent health crises. Makis has been vocal about the failures of mainstream oncology, particularly in the wake of the COVID-19 pandemic and its implications for cancer care.
The paper’s authors include leading experts in orthomolecular medicine and cancer research from various institutions worldwide, reflecting a collaborative effort to rethink cancer treatment methodologies.
Ilyes Baghli, one of the lead authors, has been instrumental in advancing the protocol’s development. He believes that integrating these repurposed drugs could provide patients with new hope in their treatment journeys.
The new protocol’s publication comes at a time when alternative cancer treatments are gaining interest among patients and practitioners seeking solutions outside conventional methods. Advocates argue that these innovative approaches could complement existing therapies and enhance patient outcomes.
As discussions around cancer treatment evolve, the implications of this groundbreaking protocol could reshape how oncologists approach therapy. The integration of repurposed drugs like Ivermectin and Mebendazole may lead to a paradigm shift in treating this complex disease.
This research underscores the importance of continued exploration into alternative treatment options as the medical community seeks effective strategies to combat cancer. The future of cancer treatment may be on the horizon with this new hybrid orthomolecular protocol.